TY - JOUR
T1 - Androgen-independent prostate cancer
T2 - Target evolution and disease dynamics
AU - Ryan, Charles J.
AU - Small, Eric J.
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2004/11
Y1 - 2004/11
N2 - Prostate cancer is a biologically diverse disease. The hallmark of the disease is its ability to regress, and ultimately regrow, following testosterone deprivation (hormone therapy). Recent developments have yielded new insights into the biological mechanisms of androgen independent growth. In turn, novel therapies directed at these mechanisms, including adrenal androgens, the insulin-like growth factors and transforming growth factor-beta, are being pursued in clinical trials.
AB - Prostate cancer is a biologically diverse disease. The hallmark of the disease is its ability to regress, and ultimately regrow, following testosterone deprivation (hormone therapy). Recent developments have yielded new insights into the biological mechanisms of androgen independent growth. In turn, novel therapies directed at these mechanisms, including adrenal androgens, the insulin-like growth factors and transforming growth factor-beta, are being pursued in clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=23744471267&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=23744471267&partnerID=8YFLogxK
U2 - 10.1016/j.ddmec.2004.10.005
DO - 10.1016/j.ddmec.2004.10.005
M3 - Review article
AN - SCOPUS:23744471267
SN - 1740-6765
VL - 1
SP - 223
EP - 228
JO - Drug Discovery Today: Disease Mechanisms
JF - Drug Discovery Today: Disease Mechanisms
IS - 2
ER -
